预测索拉非尼联合经动脉化疗栓塞治疗合并门静脉侵犯的肝细胞癌患者生存获益的预后评分模型
本观察性研究纳入2013年1月至2018年6月两家医院167例合并门静脉侵犯的肝细胞癌患者,接受索拉非尼联合经动脉化疗栓塞治疗,用训练队列(n=83)多因素Cox回归建立预后评分模型并在验证队列(n=84)确认。门静脉侵犯范围、索拉非尼相关皮肤反应和初始影像学反应三个因素被确定影响生存,评分0分、2-3分和>3分患者的中位生存期分别为38.0个月、20.0个月和7.0个月(P < 0.001)。
要点
- 合并门静脉侵犯的肝细胞癌患者接受索拉非尼联合TACE后,评分0分者中位生存38.0个月、2-3分者20.0个月、>3分者7.0个月(P < 0.001)。
- 门静脉侵犯范围、索拉非尼相关皮肤反应和初始影像学反应是影响生存的三个关键因素。
- 该预后评分模型可预测此类患者的生存获益,并在验证队列中得到确认。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: The survival benefits and which patients with advanced hepatocellular carcinoma (HCC) would benefit from sorafenib plus transarterial chemoembolization (TACE) therapy remain controversial. We aimed to develop a prognostic score model for predicting different prognoses of patients with HCC and portal vein invasion who received sorafenib plus TACE.
METHODS: This observational study included 167 patients with HCC and portal vein invasion undergoing sorafenib combined with TACE from January 2013 to June 2018 at two hospitals. Multivariate Cox regression analysis was performed using a training cohort (n = 83) to identify critical factors associated with survival. Then, a prognostic score model was established to classify different outcomes and confirmed using a validation cohort (n = 84).
RESULTS: Three factors were determined to critically impact survival in the training cohort: portal vein invasion extent, sorafenib-related dermatologic response, and initial radiological response. Using the β-coefficients of these factors, a prognostic score was calculated, and the survival time decreased as the score increased. Based on the prognostic score model, three different prognoses of patients with 0 points, 2-3 points, and > 3 points were stratified with a median survival of 38.0 months, 20.0 months, and 7.0 months, respectively (P < 0.001). Time to progression was also significantly different using the same prognostic index. The prognostic score model was confirmed by the validation cohort.
CONCLUSION: Sorafenib plus TACE is a potential therapy for selected HCC patients with portal vein invasion. This prognostic score model can predict the survival benefits for these patients.
引用
- Li JR, Wu MJ, Wang T, et al. A prognostic score model for predicting the survival benefits of patients undergoing sorafenib plus transarterial chemoembolization for hepatocellular carcinoma with portal vein invasion. Abdom Radiol (NY). 2021. PMID: 33386450. doi:10.1007/s00261-020-02897-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。